Researchers at Zhengzhou University Release New Data on Liposomes [Cancer Cell Membrane Fused Liposomal Platinum(iv) Prodrugs Overcome Cisplatin Resistance In Esophageal Squamous Cell Carcinoma Chemotherapy].

Předmět:	SQUAMOUS cell carcinoma CISPLATIN RESEARCH personnel DRUG resistance in cancer cells LIPOSOMES
Zdroj:	Drug Week; 1/5/2024, p1056-1056, 1p
Abstrakt:	Researchers at Zhengzhou University in the People's Republic of China have developed a new platinum drug delivery system called EMLipoPt(iv) that overcomes resistance to cisplatin chemotherapy in esophageal squamous cell carcinoma (ESCC). By fusing the ESCC cell membrane with liposomal Pt(iv) prodrugs, the researchers were able to enhance platinum uptake and diminish inactivation, resulting in superior tumor-targeting capacity and the ability to suppress CDDP-resistant tumor progression. The biosafety profile of EMLipoPt(iv) was also found to be better than existing treatments. This study not only presents a pioneering approach in ESCC chemotherapy but also offers a blueprint for combating drug resistance in other cancers. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu